Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy

Cerebellum

Volumn 10, Issue 2, 2011, Pages 208-217

  Öz, Gülin ^a   Iltis, Isabelle ^a   Hutter, Diane ^a   Thomas, William ^b   Bushara, Khalaf O ^c   Gomez, Christopher M ^d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Ataxia; Magnetic resonance spectroscopy; Multiple system atrophy; Neurochemical profile; SCA

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ASCORBIC ACID; CREATININE; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; GLYCEROPHOSPHORYLCHOLINE; INOSITOL; LACTIC ACID; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; PHOSPHORYLCHOLINE; SCYLLO INOSITOL; TAURINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN LEVEL; CEREBELLUM ATROPHY; CEREBELLUM VERMIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEMISPHERE; HUMAN; INSTRUMENT VALIDATION; MALE; NEUROCHEMISTRY; NEUROIMAGING; ONSET AGE; PONS; PREDICTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCALE FOR THE ASSESSMENT AND RATING OF ATAXIA; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SPINOCEREBELLAR DEGENERATION; SPINOCEREBELLAR DEGENERATION TYPE 1; SPINOCEREBELLAR DEGENERATION TYPE 2; SPINOCEREBELLAR DEGENERATION TYPE 6;

BIOLOGICAL MARKERS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; SPINOCEREBELLAR ATAXIAS;

EID: 80051795157     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-010-0213-6     Document Type: Article

References (40)

1. Schmitz-Hübsch T, Coudert M, Bauer P, Giunti P, Globas C, Baliko L, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology. 2008;71(13):982-9.
2. Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004;3(5):291-304. (Pubitemid 38510200)
3. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670-6.
4. Mueller SG, Schuff N, Weiner MW. Evaluation of treatment effects in Alzheimer's and other neurodegenerative diseases by MRI and MRS. NMR Biomed. 2006;19(6):655-68. (Pubitemid 44515610)
5. Zoghbi HY, Orr HT. Pathogenic mechanisms of a polyglutaminemediated neurodegenerative disease, spinocerebellar ataxia type 1. J Biol Chem. 2009;284(12):7425-9.
6. Di Prospero NA, Fischbeck KH. Therapeutics development for triplet repeat expansion diseases. Nat Rev Genet. 2005;6(10):756-65. (Pubitemid 41400833)
7. Prakash N, Hageman N, Hua X, Toga AW, Perlman SL, Salamon N. Patterns of fractional anisotropy changes in white matter of cerebellar peduncles distinguish spinocerebellar ataxia-1 from multiple system atrophy and other ataxia syndromes. Neuroimage. 2009;47 Suppl 2:T72-81.
8. Boesch SM, Schocke M, Burk K, Hollosi P, Fornai F, Aichner FT, et al. Proton magnetic resonance spectroscopic imaging reveals differences in spinocerebellar ataxia types 2 and 6. J Magn Reson Imaging. 2001;13(4):553-9. (Pubitemid 32231509)
9. Guerrini L, Lolli F, Ginestroni A, Belli G, Nave RD, Tessa C, et al. Brainstem neurodegeneration correlates with clinical dysfunction in SCA1 but not in SCA2. A quantitative volumetric, diffusion and proton spectroscopy MR study. Brain. 2004;127(Pt 8):1785-95. (Pubitemid 39061555)
10. Klockgether T, Skalej M,Wedekind D, Luft AR,Welte D, Schulz JB, et al. Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain. 1998;121(Pt 9):1687-93. (Pubitemid 28419974)
11. Boesch SM, Wolf C, Seppi K, Felber S, Wenning GK, Schocke M. Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging. J Magn Reson Imaging. 2007;25 (3):564-9. (Pubitemid 46355419)
12. Mandelli ML, De Simone T, Minati L, Bruzzone MG, Mariotti C, Fancellu R, et al. Diffusion tensor imaging of spinocerebellar ataxias types 1 and 2. AJNR Am J Neuroradiol. 2007;28 (10):1996-2000. (Pubitemid 350174750)
13. Schulz JB, Borkert J, Wolf S, Schmitz-Hübsch T, Rakowicz M, Mariotti C, et al. Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6. Neuroimage. 2010;49(1):158-68.
14. Lukas C, Schöls L, Bellenberg B, Rub U, Przuntek H, Schmid G, et al. Dissociation of grey and white matter reduction in spinocerebellar ataxia type 3 and 6: a voxel-based morphometry study. Neurosci Lett. 2006;408(3):230-5. (Pubitemid 44528871)
15. Della Nave R, Ginestroni A, Tessa C, Salvatore E, De Grandis D, Plasmati R, et al. Brain white matter damage in SCA1 and SCA2. An in vivo study using voxel-based morphometry, histogram analysis of mean diffusivity and tract-based spatial statistics. Neuroimage. 2008;43(1):10-9.
16. Döhlinger S, Hauser TK, Borkert J, Luft AR, Schulz JB. Magnetic resonance imaging in spinocerebellar ataxias. Cerebellum. 2008;7 (2):204-14.
17. Viau M, Boulanger Y. Characterization of ataxias with magnetic resonance imaging and spectroscopy. Parkinsonism Relat Disord. 2004;10(6):335-51. (Pubitemid 38942789)
18. Watanabe H, Fukatsu H, Katsuno M, Sugiura M, Hamada K, Okada Y, et al. Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. J Neurol Neurosurg Psychiatry. 2004;75(1):103-9. (Pubitemid 38091277)
19. Pfeuffer J, Tkáč I, Provencher SW, Gruetter R. Toward an in vivo neurochemical profile: quantification of 18 metabolites in shortecho-time 1H NMR spectra of the rat brain. J Magn Reson. 1999;141(1):104-20. (Pubitemid 129608901)
20. Tkáč I, Öz G, Adriany G, Ugurbil K, Gruetter R. In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: Metabolite quantification at 4T vs. 7T. Magn Reson Med.2009;62(4):868-79.
21. Öz G, Hutter D, Tkáč I, Clark HB, Gross MD, Jiang H, et al. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov Disord. 2010;25 (9):1253-61.
22. Öz G, Nelson CD, Koski DM, Henry PG, Marjańska M, Deelchand DK, et al. Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci. 2010;30(10):3831-8.
23. Matilla-Duenas A, Sanchez I, Corral-Juan M, Davalos A, Alvarez R, Latorre P. Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias. Cerebellum. 2010;9(2):148-66.
24. Lalonde R, Strazielle C. Spontaneous and induced mouse mutations with cerebellar dysfunctions: behavior and neurochemistry. Brain Res. 2007;1140:51-74. (Pubitemid 46371293)
25. Schmitz-Hübsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66(11):1717-20. (Pubitemid 43964628)
26. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30 (6):672-9. (Pubitemid 23360802)
27. Hochberg Y, Tamhane AC. Multiple comparison procedures. New York: Wiley; 1987.
28. 1H MRS) in patients with sporadic cerebellar degeneration. J Neuroimaging. 1999;9(2):72-7. (Pubitemid 29185671)
29. Clark JB. N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci. 1998;20(4-5):271-6.
30. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci. 1993;15(3-5):289-98. (Pubitemid 24258162)
31. 1H-MR spectroscopy: a single voxel study of the cerebellar vermis in patients with degenerative ataxias. J Magn Reson Imaging. 2009;30(1):11-7.
32. 1H magnetic resonance spectroscopy of autosomal ataxias. Brain Res. 2005;1049(2):191-202. (Pubitemid 41072935)
33. 1H MR spectroscopy metabolite measurements. Radiology. 2008;248(1):210-20.
34. Firbank MJ, Harrison RM, O'Brien JT. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease. Dement Geriatr Cogn Disord. 2002;14(2):64-76. (Pubitemid 36152947)
35. Koeppen AH. The pathogenesis of spinocerebellar ataxia. Cerebellum. 2005;4(1):62-73. (Pubitemid 40592813)
36. Robitaille Y, Lopes-Cendes I, Becher M, Rouleau G, Clark AW. The neuropathology of CAG repeat diseases: review and update of genetic and molecular features. Brain Pathol. 1997;7(3):901-26. (Pubitemid 27346734)
37. Iwabuchi K, Tsuchiya K, Uchihara T, Yagishita S. Autosomal dominant spinocerebellar degenerations. Clinical, pathological, and genetic correlations. Rev Neurol (Paris). 1999;155(4):255-70.
38. Gomez CM, Thompson RM, Gammack JT, Perlman SL, Dobyns WB, Truwit CL, et al. Spinocerebellar ataxia type 6: gaze-evoked and vertical nystagmus, Purkinje cell degeneration, and variable age of onset. Ann Neurol. 1997;42(6):933-50. (Pubitemid 28008425)
39. Koeppen AH, Dickson AC, Lamarche JB, Robitaille Y. Synapses in the hereditary ataxias. J Neuropathol ExpNeurol. 1999;58(7):748-64. (Pubitemid 29328504)
40. Ozawa T, Paviour D, Quinn NP, Josephs KA, Sangha H, Kilford L, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain. 2004;127(Pt 12):2657-71. (Pubitemid 39627375)